152 related articles for article (PubMed ID: 29626715)
1. Targeting therapeutics to bone by conjugation with bisphosphonates.
Young RN; Grynpas MD
Curr Opin Pharmacol; 2018 Jun; 40():87-94. PubMed ID: 29626715
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis.
Arns S; Gibe R; Moreau A; Monzur Morshed M; Young RN
Bioorg Med Chem; 2012 Mar; 20(6):2131-40. PubMed ID: 22341574
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Pharmacokinetics of a Bone-Targeting Dual-Action Prodrug for the Treatment of Osteoporosis.
Xie H; Chen G; Young RN
J Med Chem; 2017 Aug; 60(16):7012-7028. PubMed ID: 28699744
[TBL] [Abstract][Full Text] [Related]
4. Determination of the rat in vivo pharmacokinetic profile of a bone-targeting dual-action pro-drug for treatment of osteoporosis.
Chen G; Arns S; Young RN
Bioconjug Chem; 2015 Jun; 26(6):1095-103. PubMed ID: 25945831
[TBL] [Abstract][Full Text] [Related]
5. A peptide prodrug approach for improving bisphosphonate oral absorption.
Ezra A; Hoffman A; Breuer E; Alferiev IS; Mönkkönen J; El Hanany-Rozen N; Weiss G; Stepensky D; Gati I; Cohen H; Törmälehto S; Amidon GL; Golomb G
J Med Chem; 2000 Oct; 43(20):3641-52. PubMed ID: 11020278
[TBL] [Abstract][Full Text] [Related]
6. Novel EP4 receptor agonist-bisphosphonate conjugate drug (C1) promotes bone formation and improves vertebral mechanical properties in the ovariectomized rat model of postmenopausal bone loss.
Liu CC; Hu S; Chen G; Georgiou J; Arns S; Kumar NS; Young RN; Grynpas MD
J Bone Miner Res; 2015 Apr; 30(4):670-80. PubMed ID: 25284325
[TBL] [Abstract][Full Text] [Related]
7. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.
Hirabayashi H; Fujisaki J
Clin Pharmacokinet; 2003; 42(15):1319-30. PubMed ID: 14674786
[TBL] [Abstract][Full Text] [Related]
8. Bone-targeting macromolecular therapeutics.
Wang D; Miller SC; Kopecková P; Kopecek J
Adv Drug Deliv Rev; 2005 May; 57(7):1049-76. PubMed ID: 15876403
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate conjugation to proteins as a means to impart bone affinity.
Uludag H; Kousinioris N; Gao T; Kantoci D
Biotechnol Prog; 2000; 16(2):258-67. PubMed ID: 10753453
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin E(2) receptors as potential bone anabolic targets - selective EP4 receptor agonists.
Pagkalos J; Leonidou A; As-Sultany M; Heliotis M; Mantalaris A; Tsiridis E
Curr Mol Pharmacol; 2012 Jun; 5(2):174-81. PubMed ID: 21787288
[TBL] [Abstract][Full Text] [Related]
11. Interactions between Clinically Used Bisphosphonates and Bone Mineral: from Coordination Chemistry to Biomedical Applications and Beyond.
Gałęzowska J
ChemMedChem; 2018 Feb; 13(4):289-302. PubMed ID: 29323467
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates as a foundation of drug delivery to bone.
Uludag H
Curr Pharm Des; 2002; 8(21):1929-44. PubMed ID: 12171528
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer.
He Y; Huang Y; Huang Z; Jiang Y; Sun X; Shen Y; Chu W; Zhao C
J Control Release; 2017 Oct; 264():76-88. PubMed ID: 28842315
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Barbosa JS; Almeida Paz FA; Braga SS
J Med Chem; 2021 Feb; 64(3):1260-1282. PubMed ID: 33522236
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate prodrugs.
Vepsäläinen JJ
Curr Med Chem; 2002 Jun; 9(12):1201-8. PubMed ID: 12052172
[TBL] [Abstract][Full Text] [Related]
16. In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.
Hu S; Liu CC; Chen G; Willett T; Young RN; Grynpas MD
Osteoporos Int; 2016 Feb; 27(2):797-808. PubMed ID: 26272313
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
[TBL] [Abstract][Full Text] [Related]
18. N⁴-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate).
Schott H; Goltz D; Schott TC; Jauch C; Schwendener RA
Bioorg Med Chem; 2011 Jun; 19(11):3520-6. PubMed ID: 21536448
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery to bone and mineral deposits using bisphosphonate ligands.
Cole LE; Vargo-Gogola T; Roeder RK
Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):12-27. PubMed ID: 26482186
[TBL] [Abstract][Full Text] [Related]
20. Bone-targeting glycol and NSAIDS ester prodrugs of rhein: synthesis, hydroxyapatite affinity, stability, anti-inflammatory, ulcerogenicity index and pharmacokinetics studies.
Cai J; Duan Y; Yu J; Chen J; Chao M; Ji M
Eur J Med Chem; 2012 Sep; 55():409-19. PubMed ID: 22901311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
